New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
Decision brief
Answer first · skim in under a minute
A novel radiopharmaceutical is demonstrating promising results in patients who have previously been treated with Pluvicto, signaling a potential shift in the advanced prostate cancer treatment paradigm. This development presents significant competitive implications for companies like Abivax, Fulcrum, Convergent, and Vera.
Early AcTION data for Novartis actinium-225 PSMA-617 show a 52.5% PSA50 rate after Pluvicto, sharpening the post-Pluvicto competitive map in metastatic prostate cancer.
Contents10 sections
Key Takeaways
- FDA approved Pluvicto on March 23, 2022, after VISION (NCT03511664) showed median overall survival of 15.3 versus 11.3 months.
- AcTION phase 1 data in 101 patients reported 52.5% PSA50 in the post-Pluvicto cohort for actinium-225 PSMA-617.
- Response rates were higher in patients without prior Pluvicto, including more than 85% PSA50 in a treatment-naive subgroup.
- Radioligand therapy now represents nearly 40% of Novartis cancer research and development investment, raising the bar for rivals.
What did the AcTION study show after Pluvicto?
Novartis presented early AcTION results for actinium-225 PSMA-617 at the 2026 American Society of Clinical Oncology meeting.
Among patients previously treated with Pluvicto, 52.5% saw prostate-specific antigen fall by at least half, per Reuters coverage of the 101-patient study.
That figure corrects older secondary summaries that cited a generic 40% tumor-marker cut. PSA50 is the endpoint that matters for early radioligand reads.
Why does the post-Pluvicto setting matter commercially?
Pluvicto created a new treatment sequence problem: patients who progress after lutetium-177 PSMA therapy still need options.
As Pluvicto use expands, the absolute size of that post-progression pool grows. Any agent with clean activity after Pluvicto becomes strategically valuable for sponsors and partners.
Alpha emitters such as actinium-225 are positioned as a potency step beyond beta-emitting Pluvicto, though salivary and marrow toxicity remain central risks.
What did VISION and the FDA label establish for Pluvicto?
The FDA approved Pluvicto on March 23, 2022, for PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibition and taxane chemotherapy.
Approval rested on VISION (NCT03511664). Median overall survival was 15.3 months with Pluvicto plus best standard of care versus 11.3 months with best standard of care alone (hazard ratio 0.62).
The recommended dose is 7.4 GBq (200 mCi) every 6 weeks for up to six doses, per the FDA approval summary on PubMed.
- Median OS: 15.3 vs 11.3 months
- Hazard ratio for death: 0.62
- Dose: 7.4 GBq every 6 weeks, up to 6 doses
How should competitors read the AcTION signal?
Novartis is both the Pluvicto incumbent and a next-wave actinium developer. That dual role compresses the window for independent PSMA radioligand challengers.
Companies building post-Pluvicto assets must match not only PSA50 depth but also manage dry mouth and anemia rates that analysts flagged after the early readout.
Platform players such as Convergent Therapeutics, which is advancing actinium PSMA programs, will be judged against Novartis late-stage plans rather than against Pluvicto alone.
Which response rates sit outside the post-Pluvicto cohort?
AcTION also reported higher PSA50 rates in earlier-line subgroups. More than 85% of patients with no prior treatment and 58.8% of patients treated with chemotherapy first hit PSA50, according to the same Reuters report.
Those numbers do not replace the post-Pluvicto 52.5% figure. They show how sequence and prior therapy change expected effect size.
Radioligand therapies now account for nearly 40% of Novartis cancer research and development spending, underscoring how central this franchise has become.
What remains unproven after AcTION?
AcTION is still a phase 1 signal. It does not yet prove overall survival, radiographic progression-free survival, or a favorable risk-benefit balance versus other post-Pluvicto options.
Dry mouth and severe anemia management will decide whether actinium-225 can scale beyond early efficacy slides. Late-stage trials must confirm durability in Pluvicto-experienced men.
Until those readouts land, competitive models should treat 52.5% PSA50 as an encouraging but provisional benchmark, not a label claim.
Related NovaPharma coverage
- Pluvicto (lutetium Lu 177 vipivotide tetraxetan) drug profile
- Niowave radiopharmaceutical plant in Michigan
- Vera Therapeutics company profile
Frequently Asked Questions
What did AcTION show in patients previously treated with Pluvicto?
In the 101-patient AcTION phase 1 study of actinium-225 PSMA-617, 52.5% of patients previously treated with Pluvicto achieved a PSA50 response, meaning prostate-specific antigen fell by at least half.
When did the FDA first approve Pluvicto?
The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) on March 23, 2022, for PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibition and taxane chemotherapy, based on the VISION trial.
How does Ac-PSMA-617 differ from Pluvicto?
Pluvicto uses lutetium-177, a beta emitter. The experimental Novartis agent uses actinium-225, an alpha emitter designed to deliver higher energy over a shorter path length. Late-stage trials of the actinium program are underway.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Pluvicto.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
